Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics has confirmed the final outcome of a previously approved security consolidation affecting its ordinary fully paid shares, several classes of options, and performance rights. The consolidation, which was endorsed by shareholders at an extraordinary general meeting on 17 April 2026, is now formally recorded with the ASX, signalling completion of the capital reorganisation process and providing clarity to investors on the company’s revised security structure.
The update, lodged on 29 April 2026, supersedes earlier notifications by specifying the final consolidation result for all impacted securities under the CHM ticker. By finalising this consolidation, Chimeric aims to streamline its capital base, which may influence trading dynamics, investor perception, and the company’s flexibility in future capital management initiatives.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian biotechnology company listed on the ASX under the code CHM, focused on developing therapeutic products in the life sciences sector. Its securities include ordinary fully paid shares, options with various expiry dates and exercise prices, and performance rights that form part of the company’s capital structure.
Average Trading Volume: 220,715
Technical Sentiment Signal: Sell
Current Market Cap: A$6.63M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.